Liver fibrosis scores in patients recieving anti viral treatment
Research type
Research Study
Full title
A cohort study of transient elastography scores and outcomes in patients with liver fibrosis secondary to chronic Hepatitis C receiving direct acting anti-viral therapy in a nurse led clinic
IRAS ID
217831
Contact name
Hilary Ryan
Contact email
Sponsor organisation
Bangor University, School of Healthcare Sciences
Clinicaltrials.gov Identifier
N/A, N/A
Duration of Study in the UK
0 years, 8 months, 1 days
Research summary
The study will consider and evaluate liver fibrosis in patients recieving anti viral therapy for the treatment of hepatitis c. The study will measure liver fibrosis using transient elastography (fibroscan) before and after anti viral therapy and evaluate the statisical difference. The study will include the analysis of secondary data of patients who have completed treatment. The fibroscan assessment is offered to all patients before treatment and is routinely used in place of liver biopsy to determine the degree of fibrosis. The assessment is done as part of clinical review. Liver fibrosis is measured at baseline and again at twelve weeks following cessation of therapy which also lasts twelve weeks. The outcome measures will include an analysis of age, gender, baseline and post treatment fibrosis scores and any correlation to the medication regimen used which is dependant upon the HCV genotype. The analysis will consider the medication regimen as the dependant variable and age, gender and fibrosis scores as independent variables.
REC name
Wales REC 5
REC reference
17/WA/0021
Date of REC Opinion
22 Jan 2017
REC opinion
Favourable Opinion